Gastric cancer (GC) remains one of the most prevalent tumors worldwide and ranks third in cancer-related deaths globally. Metastasis is still a sign of end-stage GC and remains the leading cause of death in gastric cancer. The peritoneum is the most frequent site of metastasis for gastric cancer and peritoneal metastasis (PM) used to be regarded as an orphan disease with limited treatment options. In recent decades, with the application of cytoreductive surgery (CRS) and HIPEC, the prognosis of PM improved and in some selected patients, long-term survival becomes accessible. Currently, the employments of multi-omics and molecular therapy provide novel insight and approaches into the diagnosis, prediction, and even treatment for PM, and these employments start to exhibit promising prospects which leads us to step into a new era of personalized medicine for PM.
This Research Topic welcomes articles unveiling molecular mechanisms of gastric cancer peritoneal metastasis or clinical trials/research about gastric cancer peritoneal metastasis. This Research Topic aims to enhance the understanding of the molecular driver of PM in gastric cancer, explore the early-diagnosis markers in clinics, and potential therapeutic targets for gastric cancer peritoneal metastasis. Specific topics include the following:
- Molecular mechanisms that drive gastric cancer peritoneal metastasis.
- Specific biomarkers which predict the occurrence or prognosis of synchronous or metachronous peritoneal metastasis of gastric cancer.
- Radiomic characteristics of gastric cancer peritoneal metastasis.
- Multi-omics analysis which reveals the microenvironment landscape of gastric cancer peritoneal metastasis.
- Patient-derived xenografts (PDX) models and their applicability for PDX-derived metastasis.
- Establishment of patient-derived cancer organoids (PDO) for peritoneal metastasis studies.
- The role of circulating tumor cells (CTCs) in peritoneal metastasis of gastric cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Gastric cancer (GC) remains one of the most prevalent tumors worldwide and ranks third in cancer-related deaths globally. Metastasis is still a sign of end-stage GC and remains the leading cause of death in gastric cancer. The peritoneum is the most frequent site of metastasis for gastric cancer and peritoneal metastasis (PM) used to be regarded as an orphan disease with limited treatment options. In recent decades, with the application of cytoreductive surgery (CRS) and HIPEC, the prognosis of PM improved and in some selected patients, long-term survival becomes accessible. Currently, the employments of multi-omics and molecular therapy provide novel insight and approaches into the diagnosis, prediction, and even treatment for PM, and these employments start to exhibit promising prospects which leads us to step into a new era of personalized medicine for PM.
This Research Topic welcomes articles unveiling molecular mechanisms of gastric cancer peritoneal metastasis or clinical trials/research about gastric cancer peritoneal metastasis. This Research Topic aims to enhance the understanding of the molecular driver of PM in gastric cancer, explore the early-diagnosis markers in clinics, and potential therapeutic targets for gastric cancer peritoneal metastasis. Specific topics include the following:
- Molecular mechanisms that drive gastric cancer peritoneal metastasis.
- Specific biomarkers which predict the occurrence or prognosis of synchronous or metachronous peritoneal metastasis of gastric cancer.
- Radiomic characteristics of gastric cancer peritoneal metastasis.
- Multi-omics analysis which reveals the microenvironment landscape of gastric cancer peritoneal metastasis.
- Patient-derived xenografts (PDX) models and their applicability for PDX-derived metastasis.
- Establishment of patient-derived cancer organoids (PDO) for peritoneal metastasis studies.
- The role of circulating tumor cells (CTCs) in peritoneal metastasis of gastric cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
